Oryzon raises €12m to push AML and CNS pipeline
Spanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions.
ADVERTISEMENT
About Joachim Eeckhout
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 168 entries already.
Entries by Joachim Eeckhout
Telum raises €18M to push phage-derived antimicrobials toward clinic
Spanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development.
Abivax cashes in on investor enthusiasm with €807m raise
Abivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.
AlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn deal
Swedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.
Ipsen’s buying streak continues with €700m Memo deal
Paris-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline.
smartbax extends pre-series A to €6.3 m for new antibiotic
Munich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025.
Abivax answers safety questions with new data
Abivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing later this year.
Scancell plots reverse-merger path to Nasdaq
UK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets.
EMBL spin-off Epitome launches with €4M
Vienna-based Epitome Therapeutics has launched with €4 million in total financing to advance a new epigenome-editing platform designed to precisely control gene expression.
8 European VC firms to watch in 2026
European biotech enters 2026 in a strange, almost contradictory mood. The easy-money years are gone, the post-pandemic correction has done its damage, and investors are no longer rewarding science for being exciting alone. Yet the sector is far from frozen. If anything, 2025 showed that European biotech capital has become more selective, more concentrated and, in many ways, more sophisticated.